The Increasingly Human and Profitable Monoclonal Antibody Market

António L Grilo; A Mantalaris

doi:10.1016/j.tibtech.2018.05.014

The Increasingly Human and Profitable Monoclonal Antibody Market

Trends Biotechnol. 2019 Jan;37(1):9-16. doi: 10.1016/j.tibtech.2018.05.014. Epub 2018 Jun 23.

Authors

António L Grilo¹, A Mantalaris²

Affiliations

¹ Biological Systems Engineering Laboratory, Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK; ORCID: https://orcid.org/0000-0002-8592-8304.
² Biological Systems Engineering Laboratory, Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London, Exhibition Road, London SW7 2AZ, UK; ORCID: https://orcid.or/0000-0001-6183-0292. Electronic address: a.mantalaris@imperial.ac.uk.

PMID: 29945725
DOI: 10.1016/j.tibtech.2018.05.014

Abstract

The monoclonal antibody (mAb) market has changed rapidly in the past 5 years: it has doubled in size, becoming dominated by fully human molecules, launched bispecific molecules, and faced competition from biosimilars. We summarize the market in terms of therapeutic applications, type and structure of mAbs, dominant companies, manufacturing locations, and emerging markets.

Keywords: biosimilars; market analysis; monoclonal antibody.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antibodies, Monoclonal / isolation & purification*
Antibodies, Monoclonal / therapeutic use*
Global Health
Humans
Immunologic Factors / isolation & purification*
Immunologic Factors / therapeutic use*
Immunotherapy / methods*
Immunotherapy / trends*

Substances

Antibodies, Monoclonal
Immunologic Factors